Diana Sherman, MD
Internal Medicine · Gloversville, NYNPI 1942536537
Payments from drug & device makers
Across 117 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$302
- Boehringer Ingelheim$281
- Novo Nordisk$264
- Pfizer$191
- Amgen$156
- AbbVie$133
- plus $718 from 23 others
What the payments were for
- Food & beverage$2,02999%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 21 | $302 |
| Boehringer Ingelheim | 14 | $281 |
| Novo Nordisk | 15 | $264 |
| Pfizer | 9 | $191 |
| Amgen | 8 | $156 |
| AbbVie | 8 | $133 |
| AstraZeneca | 7 | $117 |
| GSK | 7 | $115 |
| UCB, Inc. | 2 | $55 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| Exact Sciences | 2 | $37 |
| Shield Therapeutics Inc | 2 | $36 |
| Lundbeck LLC | 2 | $33 |
| Johnson & Johnson | 2 | $29 |
| Collegium Pharmaceutical, Inc. | 1 | $24 |
| Abbott | 1 | $24 |
| Merck | 2 | $24 |
| Novartis | 1 | $21 |
| Adamas Pharmaceuticals, Inc. | 1 | $20 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Akcea Therapeutics, Inc. | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Radius Health, Inc. | 1 | $13 |
| Acorda Therapeutics, Inc | 1 | $12 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
How this compares
$2,044 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 181 | $174,424 |
| JardianceEmpagliflozin | 81 | $108,364 |
| TrulicityDulaglutide | 92 | $104,326 |
| EliquisApixaban | 75 | $85,458 |
| MounjaroTirzepatide | 63 | $75,463 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $40,974 |
| FarxigaDapagliflozin Propanediol | 19 | $19,925 |
| XareltoRivaroxaban | 12 | $17,618 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $10,661 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $9,918 |
| Varenicline Tartrate | 30 | $9,079 |
| OxycontinOxycodone Hcl | 22 | $9,013 |
| LinzessLinaclotide | 15 | $8,172 |
| Spiriva RespimatTiotropium Bromide | 11 | $8,144 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $6,262 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $302 | $179,789155 claims |
| Novo NordiskOzempic | $264 | $174,424181 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $281 | $116,50992 claims |
| PfizerEliquis | $191 | $85,45875 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $115 | $57,896102 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $117 | $35,71751 claims |
| Johnson & JohnsonXarelto | $29 | $17,61812 claims |
| AbbVieLinzess, Synthroid | $133 | $11,37663 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Gloversville
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.